💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 31.3% YoY to INR 880.5 Cr in FY25. In Q2 FY26, revenue reached INR 279.4 Cr, up 28% YoY. Newer hospitals were the primary growth drivers with a 110% YoY increase, while mature hospitals sustained a 19% YoY upward trajectory.

Geographic Revenue Split

Highly concentrated in North India, specifically Delhi NCR and Madhya Pradesh. Eight out of nine hospitals are localized in this region, presenting a significant geographical concentration risk.

Profitability Margins

EBITDA margin stood at 25% in FY25. For Q2 FY26, the reported EBITDA margin was 23.1%, while the adjusted EBITDA margin (excluding initial losses from new units) was a healthy 26.7%. PAT margin for FY25 was 14.8%.

EBITDA Margin

EBITDA margin was 25% in FY25, a slight decrease from 26.8% in FY24. Q2 FY26 EBITDA stood at INR 64.5 Cr, up 18% YoY, though the margin compressed by 200 bps to 23.1% due to operationalizing new units.

Capital Expenditure

Planned capex of INR 400-450 Cr in FY26 for commencing operations at MGS and MD City. This is funded through a term loan of INR 200-220 Cr and surplus liquid funds from the December 2024 QIP.

Credit Rating & Borrowing

Credit rating upgraded to A/Stable. The company maintains a strong financial risk profile with a Debt/Equity ratio of 0.00 as of March 2025, following the prepayment of most borrowings using QIP proceeds.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmacy supplies, and surgical implants represent the primary variable costs, included within operating expenses which totaled INR 660.2 Cr in FY25 (75% of revenue).

Capacity Expansion

Current operational beds increased to 1,185 in FY24. The company has an announced total capacity target of approximately 3,000 beds through greenfield and brownfield expansions.

Raw Material Costs

Operating expenses grew 34.5% YoY to INR 660.2 Cr in FY25, slightly outpacing revenue growth due to the addition of the Faridabad unit and increased specialized treatments.

Manufacturing Efficiency

Occupancy levels improved to 54% in FY24 from 45% in FY23. ARPOB increased 9% YoY to INR 25,080 in FY24, driven by specialized robotics and oncology treatments.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Achieving growth through geographic expansion in North India (Faridabad, Model Town, Agra), increasing occupancy at existing hospitals, and enhancing clinical excellence to drive higher ARPOB via oncology and robotics.

Products & Services

In-patient (IPD) and Out-patient (OPD) services, Radiation Oncology, Human Organ Transplant, Robotics Surgery, and Medical Value Travel (Medical Tourism).

Brand Portfolio

Yatharth Super Speciality Hospital.

New Products/Services

Introduction of radiation oncology, robotics surgery, and organ transplants, which contributed to the ARPOB increasing to INR 25,080.

Market Expansion

Strategic acquisitions in Faridabad, Model Town (Delhi), and Agra (Shantived) to broaden the healthcare network footprint.

Market Share & Ranking

Established market position in the Delhi NCR region with a strong brand recall and a track record of ~43% CAGR in operating income over three years.

🌍 External Factors

Industry Trends

The industry is shifting toward specialized, technology-driven care (robotics, oncology) and medical tourism. Yatharth is positioning itself as a high-end multi-specialty provider to capture this demand.

Competitive Landscape

Intense competition from large corporate hospital chains that have a pan-India presence compared to Yatharth's regional focus.

Competitive Moat

Moat is built on strong brand recall in North India, veteran leadership with 30+ years of experience, and high switching costs for patients requiring specialized, long-term treatments like oncology.

Macro Economic Sensitivity

Sensitive to inflation and fluctuating interest rates which present challenges to operational efficiency and financial stability.

Consumer Behavior

Increasing consumer preference for multi-specialty hospitals that offer comprehensive care under one roof, supporting the 54% occupancy rate.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to evolving healthcare regulatory frameworks and government-mandated pricing controls on certain medical procedures.

Taxation Policy Impact

Effective tax rate for Q2 FY26 was approximately 24.8% (INR 13.6 Cr tax on INR 54.8 Cr PBT).

Legal Contingencies

Received a favorable order from income tax authorities unfreezing provisional attached properties and fixed assets, restoring full financial flexibility for expansion.

⚠️ Risk Analysis

Key Uncertainties

Geographic concentration risk (8 of 9 hospitals in one region) and the risk of high attrition among key medical professionals.

Geographic Concentration Risk

High; majority of revenue is generated from the North India/Delhi NCR region.

Third Party Dependencies

High dependency on medical professionals and specialized surgeons for high-value clinical outcomes.

Technology Obsolescence Risk

Low risk due to proactive investment in advanced technologies like robotics and radiation oncology.

Credit & Counterparty Risk

Receivables quality is monitored; reduction in debtors older than six months is a key sensitivity factor for credit rating upgrades.